Design of multiarm PEG5K-NH2 molecules for cellular conjugation and quantification.

**Abstract:** Sensitive quantification of the pharmacokinetics of poly(ethylene glycol) (PEG) and PEGylated molecules is critical for PEGylated drug development. Here, we developed a sensitive sandwich enzyme-linked immunosorbent assay (ELISA) for PEG by tethering an anti-PEG antibody (APG3) via tethers with variable dimensions on the surface of 293T cells (293T/S-αPEG, short-type cells; 293T/L-αPEG, long-type cells; 293T/SL-αPEG, hybrid-type cells) to improve the binding capacity and detection limit for free PEG and PEGylated molecules. The detection limit of free PEG (OH-PEG3K-NH2 and CH3-PEG5K-NH2) and PEG-like molecules (CH3-PEG5K-FITC, CH3-PEG5K-SHPP, and CH3-PEG5K-NIR797) was 14–137 ng mL−1 in the hybrid-type cell-based sandwich ELISA. 293T/SL-αPEG cells also showed significantly higher sensitivity for quantification of a PEGylated protein (PegIntron) and multiarm PEGmacromolecules (eight-arm PEG20K-NH2 and eight-arm PEG40K-NH2) at 3.2, 16, and 16 ng mL−1, respectively. Additionally, the overall binding capacity of 293T/SL-αPEG cells for PEGylated macromolecules was higher than that of 293T/S-αPEG or 293T/L-αPEG cells. Anchoring anti-PEG antibodies on cells via variable-length tethers for cell-based sandwich ELISA, therefore, provides a sensitive, high-capacity method for quantifying free PEG and PEGylated molecules.

**Keywords:** PEG, anti-PEG antibody, sandwich ELISA, multiarm PEG, cell-based assay, quantification.
enzyme-linked immunosorbent assay (ELISA) is insensitive for quantification of small PEG molecules. Anti-PEG cell-based sandwich ELISA can improve the sensitivity of PEG detection by displaying unidirectional orientation of surface anti-PEG antibodies, but the detection limit remains relatively poor for PEG molecules smaller than 10000 Da because of fewer epitopes for anti-PEG antibody binding. Increasing the contact area between PEG molecules and binding antibodies may improve the quantitative sensitivity of anti-PEG cell-based sandwich ELISA. Jain and colleagues suggested that modifying the poly(2-(methacryloyloxy)ethyl succinate) (poly(MES)) brushes on porous nylon membranes can increase the surface binding area and facilitate the efficacy of lysozyme purification. The binding capacity of lysozyme from chicken egg white was enhanced 2−4-fold in poly(MES)-modified nylon membranes as compared with commercial ion-exchange membranes.

Barua et al. showed that the surface area of nanoparticles affects the specificity and capacity of modified antibodies. Rod-shaped nanoparticles provide higher surface area per unit volume compared with sphere-shaped nanoparticles and can therefore absorb higher amounts of trastuzumab antibody. The trastuzumab-coated rods exhibited greater inhibitory ability of BT-474 breast cancer cell growth in vitro as compared with soluble forms of the antibody. On the basis of these reports, we hypothesized that altering the topology of anti-PEG antibodies on the surface of cells might enhance the contact area between PEG and anti-PEG antibodies and further improve the assay sensitivity for quantification of PEG molecules.

In this study, we investigated the effect of the tether dimensions of a membrane-anchored anti-PEG antibody on the quantification sensitivity of free PEG and PEGylated molecules. The Fab domain of the AGP3 anti-PEG antibody was expressed on the surface of 293T cells via short, long, or mixed short and long tethers (Figure 1). We analyzed the capacity of the cells to bind PEG5k-FITC (FITC = fluorescein isothiocyanate) and eight-arm PEG20K-FITC and measured their detection limit in cell-based sandwich ELISA for free PEG (OH-PEG3k-NH₂ and CH₃-PEG5K-NH₂), PEG-like molecules (CH₃-PEG5K-FITC, CH₂-PEG5K-SHPP, and CH₃-PEG5K-NIR797), a PEGylated macromolecule (CH₃-PEG12K-IFNα-2b, PegIntron), and multi-arm PEG molecules (eight-arm PEG20k-NH₂ and eight-arm PEG40K-NH₂). Our data suggest that expressing anti-PEG antibodies on cells via both short and long tethers may provide a sensitive tool for quantification and pharmacokinetic studies of free PEG and PEGylated molecules.

**Experimental Section**

**Cells and Reagents.** 293T human embryonic kidney epithelial cells (American Type Culture Collection, Manassas, VA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, MO) containing 10% (v/v) heat-inactivated bovine calf serum (BCS; Thermo, Waltham, MA) and 100 units mL⁻¹ penicillin and streptomycin (Invitrogen, Calsbad, CA) at 37 °C in a humidified atmosphere of 5% (v/v) CO₂. PegIntron was from Roche (Nutley, NJ). Skim milk was purchased from BD Difco (Franklin Lakes, NJ). OH-PEG3k-NH₂ (average M₀ = 3000), CH₂-PEG5k-NH₂ (average M₀ = 5000), eight-arm PEG20K-NH₂ (average M₀ = 20000), and eight-arm PEG40K-NH₂ (average M₀ = 40000) were purchased from Fluka Chemie (Buchs, Switzerland). Poly(lactic acid) (PLA; Mₙ ≈ 60000) and polycaprolactone (PCL; Mₙ ≈ 14000) were purchased from Sigma-Aldrich. 2,2'-Azinobis[3-ethylbenzothiazoline-6-sulfonic acid] (ABTS) and 30% hydrogen peroxide were from Sigma-Aldrich. Horseradish peroxidase (HRP)-conjugated streptavidin was from Jackson Immunoresearch Laboratories (West Grove, PA). Eight-arm PEG20K-FITC, CH₂-PEG5k-FITC, CH₂-PEG5k-3-(4-hydroxyphenyl)propionic acid N-hydroxysuccinimide ester (SHPP), and CH₂-PEG₄₀-near-infrared 797 (NIR797) were synthesized as previously described.

**Plasmid Construction.** The V₁-C₅ and V₅-H₁ domains of the anti-PEG antibody were cloned from cDNA prepared from the AGP3 hybridoma following a previously described method. Primers used in the cloning of V₁-C₅ and V₅-H₁ were as follows: V₁-C₅ sense, 5'-ttgctggggccacgcggcagttggtgagcaggggt3'; V₁-C₅ antisense, 5'-cctggctggcaacactcattccgtaggaaagtgtc3'; V₅-H₁ sense, 5'-gaactgtagaaccgcttgggctgg3'; V₅-H₁ antisense, 5'-cgagctcagctggcacagttgagt3'; V₅-H₁ antisense, 5'-cagggcagctggacaactcctag3'. The light- and heavy-chain sequences, joined by a furin-2A protease cleavage site, were subcloned into two lentiviral vectors, pLKO_AS3-eB7 and pLKO_AS3-PTK7-eB7, by use of HindIII and SalI restriction sites. The expression vectors, pLKO_AS3-AGP3-eB7 and pLKO_AS3-AGP3-PTK7-eB7, encode an anti-PEG Fab fused to the immunoglobulin C2-type extracellular transmembrane–cytosolic domains of the mouse B7-1 antigen (eB7) or immunoglobulin C2-type domain of the tyrosine protein kinase 7 (PTK7)-eB7 (Figure 2A).

**Generation of Short-, Long- and Hybrid-Tethered Anti-PEG-Expressing Cells by Lentiviral Transduction.** Pseudotyped lentiviruses were generated by cotransfecting pLKO_AS3-AGP3-eB7 or pLKO_AS3-AGP3-PTK7 with pCMVΔR8.91 or pMD.G (Academia Sinica, Taipei, Taiwan), respectively, in 293T cells by PureFecion (System Biosciences, Palo Alto, CA). Two days after transfection, the culture
medium was filtered, mixed with 8 μg mL⁻¹ Polybrene (Sigma-Aldrich), and added to 293T cells. Following lentiviral transduction, the cells were selected in 2 μg mL⁻¹ puromycin- or 100 μg mL⁻¹ hygromycin-containing medium and sorted on a FACS Cantor (Beckman Coulter, Brea, CA) to generate anti-PEG cells that stably expressed approximately equal levels of short-, long-, or hybrid-tethered anti-PEG antibodies on their surface.

**Western Blot Analysis of the Anti-PEG-Expressing Cells.** 293T/S-αPEG (short-type), 293T/L-αPEG (long-type), and 293T/SL-αPEG (hybrid-type) cells (2 × 10⁵) were collected and boiled for 5 min in nonreducing sample buffer. The samples were electrophoresed in an 8% sodium dodecyl sulfate (SDS)—polyacrylamide gel under nonreducing conditions and then transferred onto nitrocellulose paper (Merck Millipore, Billerica, MA). After blocking with 5% skim milk, the membrane was incubated with either 0.4 μg/mL HRP-conjugated goat antianti-PEG Fab was determined by staining the cells with 3.75 μg mL⁻¹ anti-PEG antibody (Novus Biologicals, Littleton, CO). After being incubated with biotinylated CH₃-PEG5K-FITC or mouse antihuman β-actin antibody (Jackson Immunoresearch Laboratories) or mouse antihuman β-actin antibody (Novus Biologicals, Littleton, CO). After being washed four times with PBST (PBS containing 0.05% Tween 20) and once with PBS, the membrane stained with anti-β-actin antibody was then incubated with HRP-conjugated goat antimouse IgG F(ab')₂ antibody. After extensive washing, the blot was visualized by enhanced chemiluminescence detection according to the manufacturer’s instructions (Merck Millipore). The bands of anti-PEG Fab and β-actin were quantified by densitometry with the Gel-Pro Analyzer 4.0 software.

**Fluorescence-Activated Cell Sorting Analysis of the Anti-PEG-Expressing Cells.** Surface expression of the anti-PEG Fab was measured by staining the cells with 3.75 μg mL⁻¹ FITC-conjugated goat antianti-PEG Fab was determined by incubating the cells with 10 μg mL⁻¹ CH₃-PEG5K-FITC or 250 ng mL⁻¹ eight-arm PEG20K-FITC in PBS containing 0.05% (w/v) bovine serum albumin (BSA) on ice. The PEG binding activity of membrane-tethered anti-PEG Fab was determined by incubating the cells with 10 μg mL⁻¹ CH₃-PEG5K-FITC or 250 ng mL⁻¹ eight-arm PEG20K-FITC in PBS containing 0.05% (w/v) BSA on ice. After removal of unbound antibodies, CH₃-PEG5K-FITC, or eight-arm PEG20K-FITC by extensive washing in cold PBS containing 0.05% (w/v) BSA, the surface fluorescence of the viable cells was measured on a FACSscan flow cytometer (BD Biosciences, San Jose, CA), and the fluorescence intensities were analyzed with FlowJo7.6.1 software (Tree Star, San Carlos, CA). The binding capacities of hybrid-type (293T/SL-αPEG), short-type (293T/S-αPEG), and long-type (293T/L-αPEG) cells for free PEG and PEGylated molecules were determined by incubating the cells with serially diluted CH₃-PEG5K-FITC probe (10, 3.3, 1.1, 0.4, 0.12, and 0.04 μg mL⁻¹) or eight-arm PEG20K-FITC probe (2500, 833, 278, 93, 31, and 10.3 ng mL⁻¹) in PBS containing 0.05% (w/v) BSA on ice. After removal of unbound probes by extensive washing in cold PBS containing 0.05% (w/v) BSA, the surface fluorescence of the viable cells was measured on a FACSscan flow cytometer.

**Anti-PEG Cell-Based Sandwich ELISA.** In all sandwich ELISA experiments, PBS containing 2% (w/v) skim milk was used as the sample dilution buffer and PBS was used as the wash buffer. The short-, long-, or hybrid-tethered anti-PEG cells (2 × 10⁵ cells per well) were seeded overnight in 96-well plates (Nalge Nunc International, Roskilde, Denmark) coated with 50 μg mL⁻¹ poly-o-lysine (Corning, New York) in culture medium. After extensive washing, the cells were fixed with 2% (w/v) paraformaldehyde for 5 min at room temperature (rt). The fixed reaction was stopped by 0.1 M glycine for 30 min at rt. In our previous study, there was no significant difference in anti-PEG antibody binding in fixed and nonfixed anti-PEG (AGP3)-expressing cells. The plates were blocked with 5% (w/v) skim milk in PBS for 2 h at 37 °C. Graded concentrations of PLA, PCL, OH-PEG3K-NH₂, CH₃-PEG5K-NH₂, CH₃-PEG5K-FITC, CH₃-PEG5K-SHPP, CH₃-PEG5K-NIR797, PEGIntron (Schering-Plough, Kenilworth, NJ), eight-arm PEG20K-NH₂, or eight-arm PEG40K-NH₂ were added to the wells (50 μL per well) at rt for 1 h. After washing, the cells were sequentially incubated with biotinylated AGP4 (0.25 μg per well) and HRP-conjugated streptavidin (HRP—streptavidin, 50 ng per well). The plates were washed with PBS, and the bound peroxidase activity was measured by adding 150 μL of ABTS solution [0.4 mg mL⁻¹, 2,2′-azinobis[3-ethylbenzothiazoline-6-sulfonic acid] (Sigma-Aldrich), 0.01% (v/v) H₂O₂, and 100 mM phosphate—citrate, pH 4.0] per well for 1 h at rt. Color development was measured at 405 nm on a microplate reader (Molecular Devices, Menlo Park, CA).

**Modeling the Structures and Calculating the Length of Short-Type (AGP3-eB7) and Long-Type (AGP3-PTK7) Anti-PEG Fab.** The three-dimensional structure of short-type (AGP3-eB7) and long-type (AGP3-PTK7) anti-PEG Fab was modeled by SWISS-Modeling (https://swissmodel.expasy.org/), which is a fully automated protein structure homology-modeling server. The Ig-like C2 domain of eB7 (residues 143–246) was built using B7-1 (PDB code 1DR9, 58.7% sequence identity) as a template. The 247–268 transmembrane region and the 269–306 cytoplasmic domain of eB7 were built using CD4 (PDB code 2KLX, 23.33% identity). The first through sixth N-terminal Ig-like C2 domains (residues 31–586) and the seventh domain (residues 578–680) of PTK7 were built using titin (PDB code 3B43, 23.53% identity) and Sidekick-1 (PDB code 5K6W, 38.24% identity). The structure of AGP3 anti-PEG Fab was modeled by Discovery Studio (DS) software. The modeled fragment structures were merged to generate the structural model of AGP3-eB7 and AGP3-PTK7. The structures were then visualized and the molecular length of each domain was calculated by PyMol software (DeLano Scientific).

**Statistical Analysis.** All the readings were background-adjusted by subtracting the absorbance of a blank control in the ELISA procedures. The detection limit of the ELISA experiments was determined by using an independent t test to compare the statistical significance of the differences between the controls and samples (free PEG and PEGylated molecules). Data were considered significant at a P value of less than 0.05.

**RESULTS AND DISCUSSION**

**Characterization of Short-, Long-, or Hybrid-Tethered Anti-PEG Antibody-Expressing 293T Cells.** To increase antigen–antibody interactions on the cell surface, we expressed anti-PEG antibodies (AGP3) with different lengths of tethers on the membrane of 293T cells. We selected the immunoglobulin-like (Ig-like) C2-type extracellular transmembrane–cytosolic domains of the mouse B7−1 antigen (eB7) as a short tether and the extracellular region of the tyrosine protein kinase 7 (PTK7), which contains seven Ig-like C2-type domains, as a long tether. We constructed two lentiviral vectors, pLKO_AS3-AGP3-eB7 and pLKO_AS3-AGP3-PTK7, to
directly express and anchor the Fab fragment of AGP3 (anti-PEG antibody) on the cells. In these two constructs, the AGP3 light (VL-C\(\kappa\)) and heavy (VH-CH1) chains are separated by a furin cleavage site and 2A peptide (Figure 2A), which allows antibody expression from a single open reading frame. 28 Human embryonic kidney epithelial 293T cells were infected with recombinant lentivirus containing pLKO_AS3-AGP3-eB7 or pLKO_AS3-AGP3-PTK7 plasmid individually or in combination to obtain 293T/SL-\(\alpha\)PEG (hybrid-type), 293T/\(S\)-\(\alpha\)PEG (short-type), and 293T/L-\(\alpha\)PEG (long-type) cells. The cell lysate of each type of cell was separated by SDS−polyacrylamide gel electrophoresis (PAGE) under nonreducing conditions and analyzed by Western blotting using a mouse F(ab\('\))\(_2\) domain specific antibody to confirm the expression of AGP3-eB7 and AGP3-PTK7. Figure 2B shows that AGP3-eB7 and AGP3-PTK7 were detected with apparent molecular weights of approximately 106400 and 197600, respectively, consistent with their expected molecular weights. The ratio of anti-PEG Fab to \(\beta\)-actin in 293T/\(S\)-\(\alpha\)PEG, 293T/L-\(\alpha\)PEG, and 293T/SL-\(\alpha\)PEG cells approached 1, indicating that the expression levels of anti-PEG Fab in each type of cell were similar. The membrane expression and function of the anti-PEG Fab on 293T/\(S\)-\(\alpha\)PEG, 293T/L-\(\alpha\)PEG, and 293T/SL-\(\alpha\)PEG cells was confirmed by flow cytometry after the cells
were directly stained with FITC-conjugated antimouse F(ab′)2 antibodies, CH3-PEG5K-FITC probe, or eight-arm PEG20K-FITC probe to detect functional antibody binding. Figure 2C shows that AGP3-eB7, AGP3-PTK7, and AGP3-eB7 plus AGP3-PTK7 Fab fragments were expressed at similar levels on 293T/αPEG, 293T/αPEG, and 293T/αPEG cells, respectively. All anti-PEG Fabs expressed on cells specifically bound CH3-PEG5K-FITC probe (Figure 2D) and eight-arm PEG-FITC probe (Figure 2E), indicating that surface-displayed anti-PEG Fab maintained PEG binding activity.

To analyze the cross-reactivity of anti-PEG antibody-expressing 293T cells, we coated 293T/αPEG cells in 96-well plates, followed by addition of serial dilutions of CH3-PEG5K-NH2 (PEG; Mw ≈ 5000), poly(lactic acid) (PLA; Mw ≈ 60000), and polycaprolactone (PCL; Mw ≈ 14000). PLA and PCL polymers possess structures similar to that of PEG and also have been approved by the FDA for specific applications in humans, such as for drug delivery.30,31 Captured molecules were quantified by sequential addition of biotinylated AGP4 anti-PEG antibody, HRP-conjugated streptavidin, and ABTS substrate. Figure 2F shows that anti-PEG Fabs expressed on cells can specifically bind to PEG in a dose-dependent manner but not PLA or PCL polymers. These results indicate that we have successfully established short-, long-, or hybrid-tethered anti-PEG antibody-expressing 293T cells, which can specifically capture PEG molecules with minimal cross-reactivity against other polymers.

Binding Capacity of PEGylated Molecules on Short-, Long-, or Hybrid-Tethered Anti-PEG Antibody-Expressing 293T Cells. To investigate whether the antibody topology can enhance the antigen binding capacity of cells, we measured the binding of small and multiarm PEG-like molecules to 293T/αPEG (hybrid-type), 293T/αPEG (short-type), and 293T/αPEG (long-type) cells by directly staining each type of cell with serial dilutions of CH3-PEG5K-FITC or eight-arm PEG20K-FITC and then detecting the fluorescence signal by flow cytometry. Figure 3 shows that the hybrid-type cells (293T/αPEG) produced a higher fluorescence intensity of CH3-PEG5K-FITC (Figure 3A) and eight-arm PEG20K-FITC (Figure 3B) compared with short-type (293T/αPEG) and long-type (293T/αPEG) cells, indicating that hybrid-type cells have at least 10-fold and 80-fold enhanced binding capacity of CH3-PEG5K-FITC and eight-arm PEG20K-FITC, respectively, in comparison with uniform-length cells (293T/αPEG and 293T/αPEG). This result suggests that the variable topology created by short and long tethers may increase the contact with PEG and improve binding to small and multiarm PEG-like molecules.

Quantiﬁcation of Free PEG and PEG-like Molecules by Anti-PEG Cell-Based Sandwich ELISA. To investigate the influence of the antibody topology on the assay sensitivity in a cell-based sandwich ELISA, we coated 293T/αPEG, 293T/αPEG, and 293T/αPEG cells on 96-well plates followed by adding serial dilutions of free PEG (OH-PEG3K-NH2 and CH3-PEG5K-NH2) to the wells. The absorbance signals were detected by a cell-based sandwich ELISA using biotinylated AGP4 anti-PEG antibody as the capture reagent and HRP-conjugated streptavidin as the detection antibody. Figure 4 shows that the hybrid-type cells (293T/αPEG) produced a higher absorbance intensity of OH-PEG3K-NH2 (Figure 4A) and CH3-PEG5K-NH2 (Figure 4B) compared with short-type (293T/αPEG) and long-type (293T/αPEG) cells, respectively, in comparison with uniform-length cells (293T/αPEG and 293T/αPEG). This result suggests that the variable topology created by short and long tethers may increase the contact with PEG and improve binding to small and multiarm PEG-like molecules.
PEG$_{5K}$-NH$_2$) and PEG-like (CH$_2$-PEG$_{5K}$-FITC, CH$_2$-PEG$_{5K}$-SHPP, and CH$_2$-PEG$_{5K}$-NIR797) molecules. Captured molecules were then quantified by sequential addition of biotinylated AGP4 anti-PEG antibody, HRP-conjugated streptavidin, and ABTS substrate. Figures 4 and 5 show that the binding capacities of 293T/SL-aPEG cells for different lengths of free PEG molecules and all three PEG-like molecules were significantly enhanced compared with those of 293T/S-aPEG and 293T/L-aPEG cells. The HRP signal could be amplified by 1.2–183-fold at concentrations ranging from 41 to 10000 ng mL$^{-1}$ free PEG and PEG-like molecules. 293T/SL-aPEG cells could sensitively detect free PEG molecules at a concentration of 41 ng mL$^{-1}$ and PEG-like molecules at concentrations ranging from 14 to 137 ng mL$^{-1}$, whereas 293T/S-aPEG and 293T/L-aPEG cells showed poor detection ability at the same concentrations. The poor detection ability of uniform-length anti-PEG Fab-expressing cells may be caused by the release of fewer epitopes of PEG molecules after binding to captured antibody than hybrid-type cells, thereby decreasing the binding of detective antibodies and signal amplification (Figure 7). Taken together, these results indicate that the hybrid-type anti-PEG Fab-expressing cells (293T/SL-aPEG cells) provided higher binding capacity and detection limit for free PEG and PEG-like molecules.

Limited sensitivity is the major stumbling block in traditional quantitative methods for quantifying PEG small molecules. High-performance liquid chromatography (HPLC), especially HPLC coupled with tandem mass spectrometry (HPLC/MS/MS), is a powerful analytical technique that is widely used for the analysis of PEG and PEGylated small drugs. However, multiple pretreatment steps are required to reduce the clinical sample complexity before analysis, and the low tolerance to contamination from surrogate peptides and other truncated metabolite species present in clinical samples restricts its application.

Radiolabeling offers a highly sensitive method to determine the pharmacokinetics of PEG and PEGylated compounds, but incorporation of radioisotopes may alter the pharmacokinetic properties of small molecules. Methoxy-PEG (mPEG), which is most commonly used for PEG modification due to its minimized cross-linking possibility, is difficult to directly label by radioisotopes. Safety and disposal issues related to radioisotopes, and the sophisticated equipment used, also limit its universality. Although anti-PEG Ab-based ELISA and anti-PEG cell-based sandwich ELISA could specifically and sensitively detect PEGylated proteins and PEGylated nanoparticles in biological fluid, they still suffered from low sensitivity for quantification of free PEG and PEG-like molecules. Our results show that the hybrid-type anti-PEG antibody-expressing 293T cells (293T/SL-aPEG cells) can significantly increase the PEG small-molecule detection limit and binding capacity in comparison with uniform-length anti-PEG antibody-expressing cells (293T/S-aPEG and 293T/L-aPEG cells). We believe that the steric space created by hybrid-lengthsurface anti-PEG antibody-expressing cells can more efficiently and sensitively analyze the pharmacokinetics of PEG small molecular drugs.

Enhancement of the topological space for antigen–antibody interactions can improve the binding capacity and detection limit of cell-based sandwich ELISA. Brown and colleagues showed that immunoglobulin (Ig) projecting from an antigen molecule adsorbed to a microtiter well surface is more accessible for further interactions with a labeled probe and exhibited a 3–5-fold increase in binding capacity as compared to Ig directly bound to the well surface, suggesting that steric effects may be important in determining the detection limit of ELISA. Sakhnini et al. demonstrated that a Fab fragment immobilized via aldehyde functional groups on a resin with smaller pores, i.e., larger surface area, provided a 9-fold increase in DBC$_{100\%}$ (dynamic binding capacity at 100% breakthrough) relative to monoclonal antibody immobilized on CNBr-activated Sepharose beads. Kumada and colleagues also found that coating antibodies in the same orientation on a PS microwell plate could increase the surface area for antigen–antibody interactions and elevate the detection limit in comparison with randomly orientated capture antibodies in traditional ELISA. In our study, we demonstrated that anchoring anti-PEG Fab fragments with a combination of tether lengths on 293T cells (293T/SL-aPEG cells) could significantly increase the binding capacity of CH$_2$-PEG$_{5K}$-FITC and eight-arm PEG$_{20K}$-FITC probes and produce a higher detection limit of free PEG molecules, PEG-like molecules, and PEGylated macromolecules compared to those of uniform-length anti-PEG Fab-expressing cells (293T/S-aPEG and 293T/L-aPEG cells) in cell-based sandwich ELISA. The higher capacity and detection limit of 293T/SL-aPEG cells may result from increasing the loading of PEG molecules and releasing more epitopes for the detective antibody in cell-based sandwich ELISA (Figure 7). The concept of enhancing the topological space of antigen–antibody interactions may be useful for other antibodies and biomaterials. We believe that the unidirectional organization (outward organization) and variable topology of anti-PEG antibodies on the cell surface can bind more repeating epitopes on PEG to improve the binding capacity and sensitive detection of free PEG and PEGylated molecules.

Figure 5. Quantitative cell-based ELISA for PEG-like molecules. Sandwich ELISAs with 293T/SL-aPEG (△), 293T/S-aPEG (●), and 293T/L-aPEG (□) cells as the capture reagents and the biotinylated anti-PEG antibody (AGP4) as the detection antibody were used to measure the concentration of (A) CH$_2$-PEG$_{5K}$-FITC, (B) CH$_2$-PEG$_{5K}$-SHPP, or (C) CH$_2$-PEG$_{5K}$-NIR797. The mean absorbance values (405 nm) of triplicate determinations are shown. The bars indicate the SD.
Quantitation of PEGylated Protein and Multiarm PEG Macromolecules by Anti-PEG Cell-Based Sandwich ELISA. We also analyzed the detection limit of 293T/SL-αPEG (hybrid-type), 293T/S-αPEG (short-type), and 293T/L-αPEG (long-type) cells for a PEGylated protein (CH3-PEG12K-IFNα-2b; PegIntron) and multiarm PEG macromolecules (eight-arm PEG20K-NH2 and eight-arm PEG40K-NH2) using a previously described procedure. As shown in Figure 6, the detection limits of 293T/SL-αPEG cells for quantifying PegIntron, eight-arm PEG20K-NH2, and eight-arm PEG40K-NH2 were as low as 3.2−16 ng mL−1. More sensitive detection compared to that for measurement of free PEG molecules is attributed to more binding epitopes on the long PEG molecules on PegIntron and the multiarm PEG molecules. The binding capacity of 293T/SL-αPEG cells was significantly improved at high concentrations (in the range from 16 to 2000 ng mL−1) of PEGylated proteins \((P < 0.001)\) and multiarm PEG macromolecules (eight-arm PEG20K-NH2 and eight-arm PEG40K-NH2; \(P < 0.05−0.001\)) compared with that of 293T/S-αPEG and 293T/L-αPEG cells. Together, these results suggest that the 293T/SL-αPEG cells possess a larger binding capacity for detecting PEGylated protein and multiarm PEG molecules in comparison to cells expressing uniform-length anti-PEG antibodies.

Development of a universal tool for the quantification of PEG and PEGylated molecules is desirable. PEG is a water-soluble, nontoxic, low-immunogenicity, biocompatible polymer that has been approved by the FDA for human intravenous, oral, and dermal applications.1 PEG with various molecular weights has been widely used in biopharmaceuticals. For example, poly(ethylene glycol) 3350 (PEG-3350) is the major component of laxatives (e.g., TriLyte or MiraLax) for treating constipation,37 methoxy PEG-2K (mPEG2K) covalently conjugated on zidovudine (AZT) is used to treat acquired immune deficiency syndrome (AIDS),38 mPEG30K is also used for liposomal doxorubicin modification (Lipo-Dox) for treatment of several types of cancer,15 and mPEG30K conjugated to epoetin β (Mircera) is used for treating anemia.7 Thus, it is important to develop a universal tool for the quantification of different lengths of PEG and PEGylated molecules. Our results show that all of the hybrid-type (293T/SL-αPEG), short-type (293T/S-αPEG), and long-type (293T/L-αPEG) cells could sensitively quantify free PEG molecules, PEG-like molecules, and PEGylated macromolecules. Notably, the hybrid-type 293T
cells (293T/SL-αPEG cells) displayed the highest binding capacity and sensitivity for quantifying free PEG and PEGylated molecules in a cell-based sandwich ELISA. We think that this universal quantitative tool can properly quantify different lengths of PEG molecules and accelerate the development of PEGylated drugs in research laboratories and in industry.

It is important to develop a low-cost and convenient method for quantitative measurement of PEG and PEGylated drugs during drug development. In traditional ELISA, a high purity of capture antibodies is needed for sample detection. The complex process of antibody purification may add cost and time and even damage the structure of the antibodies, and further affect the antibody’s ability to bind to the target antigen. On the other hand, endogenous proteins or clotting factors in serum can also affect the accuracy of traditional quantitative ELISA.  

To avoid a similar situation and simplify the manufacturing process of the drug quantitative ELISA, we generated the anti-PEG antibody-expressing 293T cells (293T/SL-αPEG cells) as a PEG capture reagent. The 293T/SL-αPEG cells can continuously provide a stable and high-quality source of PEG capture cells without requiring additional purification of PEG capture antibodies. We previously showed that skim milk or serum not only did not interfere with the assay detection limit but also greatly enhanced the detection limit of the assay for PEG and PEGylated molecules in the anti-PEG cell-based sandwich ELISA.  

Additionally, we also optimized the binding capacity of PEG and PEGylated molecules in 293T/SL-αPEG cells by adjusting the ratio of short-type (AGP3-eB7) and long-type (AGP3-PTK7) anti-PEG antibodies on the cell surface. Unfortunately, the lack of a well-established production line limits the wide usage and/or commercialization of cell-based sandwich ELISA kits in the current market. We expect that the optimized hybrid-type anti-PEG antibody-expressing cells will provide a lower cost, convenient, and sensitive tool for monitoring PEGylated drugs in clinical samples.

**Speculative Model for a Higher Capacity and Detection Limit of PEG Molecules in Hybrid-Tethered Anti-PEG Antibody-Expressing 293T Cells.** To attempt to explain why the capacity of PEG molecules can be elevated on hybrid-type anti-PEG cells (293T/SL-αPEG cells), we predicted the three-dimensional structure of short-type (AGP3-eB7) and long-type (AGP3-PTK7) anti-PEG Fab with an automated protein structure homology-modeling server, SWISS-Modeling, and calculated the molecular length of each domain by PyMol software (DeLano Scientific). We took PEG1k as an example and assumed an average PEG1k chain length of 5 nm on the basis of the commonly reported value of about 5 nm by Cauda,  

Unfortunately, the lack of a well-established production line limits the wide usage and/or commercialization of cell-based sandwich ELISA kits in the current market. We expect that the optimized hybrid-type anti-PEG antibody-expressing cells will provide a lower cost, convenient, and sensitive tool for monitoring PEGylated drugs in clinical samples.

**CONCLUSIONS**

In summary, we demonstrated that varying the topology of anti-PEG antibodies on 293T cells (293T/SL-αPEG cells) allows a higher binding capacity and detection limit for free PEG and PEGylated molecules compared with that of uniform-length anti-PEG antibody-expressing cells (293T/SL-αPEG and 293T/L-αPEG cells) in a cell-based sandwich ELISA system. We suggest that this hybrid-length anti-PEG Fab-expressing cell-based sandwich ELISA has the following advantages and potential: (1) more sensitive quantification of PEG and PEGylated molecules; (2) single cloned and membrane anti-PEG Fab highly expressing 293T cells that can continuously provide a stable and high-quality source of PEG capture cells for high-throughput measurement of samples; (3) optimization of the binding capacity of PEGylated molecules in 293T/SL-αPEG cells by adjusting the ratio of short-type (AGP3-eB7) and long-type (AGP3-PTK7) anti-PEG antibodies on the cell surface; (4) potential application of the concept of increasing binding capacity by enhancing the surface area for ligand–receptor interactions in other research fields (e.g., protein purification); (5) potential wide-range use for quantification of PEG-like and PEGylated molecules and consequent acceleration of the process of drug development. We believe that the hybrid-length anti-PEG Fab cell-based sandwich ELISA provides a sensitive, convenient, and universal method that may be used in basic research laboratories and pharmaceutical companies to study the pharmacokinetics of PEG and PEGylated molecules.
for the Top 500 Universities Grants (KMU-TP105C00 and KMU-DT106003). This study was also supported partially by the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan (BM10501010045), a grant from the Program for Translational Innovation of Biopharmaceutical Development-Technology Supporting Platform Axis, Academia Sinica, Taiwan (GR1C06TSPA01), and a grant from the Health and Welfare Surcharge of Tobacco Products (MOHW106-TDU-B212-144007).

**REFERENCES**


